Photo taken from European Society for Radiotherapy and Oncology/LinkedIn
Aug 6, 2024, 16:48
Findings from key trials SC.24 and RTOG 0631 and influence SBRT’s effectiveness – European Society for Radiotherapy and Oncology
European Society for Radiotherapy and Oncology, shared a post on LinkedIn:
“Although some guidelines support the use of SBRT for oligometastatic diseases, its role in painful bone metastases remains debated.
Discover the latest findings from key trials such as SC.24 and RTOG 0631, and understand the nuances that influence SBRT’s effectiveness.
Read the full report on this topic that was discussed at ESTRO24″
Source: European Society for Radiotherapy and Oncology/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28